In order to improve the disease-selectivitysafety of antibody drugs, we use the autologous hinge as an antibody lockuse protease substrate peptide as linker to generate pro-antibody. Only in the disease area, the overexpressed protease will restore the function of the antibody. The antibody lock can improve the safety of antibodiesthe quality of patient medications. This technology has global patents (granted in 15 countries)technology transfer experience. We believed that the universal antibody lock will bring a revolutionary breakthrough in antibody drugs.

"1. We are the first one to use autologous antibody hinge as antibody lock, which is unique to the other masking strategies in the world.
2. The autologous Ab lock has low immunogenicity will not induce unwanted immune responses.
3. Our antibody lock would provide spatial hindrance to antibody after protease hydrolysis can completely remove from antibody.
4. Due to the framework of Ab is highly conserved, the Ab lock can be applied in most therapeutic Ab drugseasily to co-develop with any pharmaceutical company worldwide. We believe it has unlimited business opportunities."

"Antibody lock can improve the disease selectivity of antibodies,has three major industrial applications, 
1. [Revive] antibodies that have been withdrawn due to severe clinical side effects, 
2. [Value-added] the existing antibody drugs by enhancing safety,
3. [newborn] with antibody lock, the patent-expired antibodies can be a new drug. 
The antibody lock platform has a complete global patent, it can extensively cooperate with worldwide pharmaceutical companies to develop antibody drugs. We believe antibody lock has outstanding influence to the mainstream antibody-drug industry."

天使投資人、策略合作夥伴